Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMO To Shed “Orphaned” Products, Prime Tecnis Acrylic IOL For U.S. Launch

This article was originally published in The Gray Sheet

Executive Summary

Advanced Medical Optics plans to increase the contribution of "promoted products" from 80% of revenue to 90% by the fiscal third quarter of 2006

You may also be interested in...



Refractive IOL Market On Track To Approach $1 Bil. By 2010, AMO Asserts

Advanced Medical Optics projects the worldwide refractive intraocular lens market will reach $180 mil.-$200 mil. this year and approach $1 bil. by 2010, based on accelerating uptake of the technology

Refractive IOL Market On Track To Approach $1 Bil. By 2010, AMO Asserts

Advanced Medical Optics projects the worldwide refractive intraocular lens market will reach $180 mil.-$200 mil. this year and approach $1 bil. by 2010, based on accelerating uptake of the technology

AMO launches Tecnis acrylic

Foldable intraocular lens intended to improve functional vision in cataract patients launches Aug. 10, following supplemental PMA approval in April. The Tecnis line was originally cleared in 2001, but AMO was able to incorporate the acrylic platform following the firm's April 2004 acquisition of Pfizer's ophthalmic surgical business. CEO Jim Mazzo believes that U.S. surgeons prefer acrylic lenses to silicone devices (1"The Gray Sheet" June 13, 2005, p. 21)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel